Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | HAT1 | O14929 | 3/20 | 0.43 |
| ▸ | EP300 | Q09472 | 3/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834749 | 0.84 | GAA (0.48) | GABRA1GABRB2CFTRPRKAB2PRKAG1 | |
| SCHEMBL6961431 | 0.83 | ALDH1A1 (0.44) | GABRA1GABRB2CFTRPOLBKMT2A | |
| SCHEMBL6667391 | 0.83 | KDM4E (0.41) | GABRA1GABRB2CFTRHAT1EP300 | |
| SCHEMBL7843026 | 0.82 | GABRA1 (0.45) | GABRA1GABRB2CFTRPRKAB2PRKAG1 | |
| SCHEMBL7845927 | 0.81 | HAT1 (0.44) | GABRA1GABRB2CFTRHAT1EP300 | |
| SCHEMBL6958611 | 0.81 | ALDH1A1 (0.44) | GABRA1GABRB2CFTRPOLBKMT2A | |
| SCHEMBL6667428 | 0.81 | ALDH1A1 (0.51) | CFTRPOLBKMT2A | |
| SCHEMBL6950306 | 0.80 | ALDH1A1 (0.43) | GABRA1GABRB2CFTRPOLBKMT2A | |
| SCHEMBL6959857 | 0.78 | ALDH1A1 (0.45) | POLBKMT2A | |
| SCHEMBL7845316 | 0.77 | HSD17B10 (0.44) | GABRA1GABRB2CFTRLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292575-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2001098275-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2004019932-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6653307-B2 | Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, ZC3HAV1L | GABRA1 4527/4885GABRB2 4426/4885CFTR 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.